TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02649855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: It is commercially available. It will be administered at 75 mg/m(2) intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: It is commercially available. It will be administered at 75 mg/m(2) intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: It is commercially available. It will be administered at 75 mg/m(2) intravenously.
Study: NCT03058666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Calfactant
Description: Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solarys
Description: Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
Study: NCT02953236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented massage
Description: The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual massage
Description: The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
Study: NCT03118999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-FFA
Description: Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-FFA
Description: Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-MAG
Description: Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-MAG
Description: Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-EE
Description: Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-EE
Description: Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
Study: NCT03838016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babble Boot Camp
Description: The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babble Boot Camp
Description: The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
Study: NCT00671372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulanermin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulanermin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intravenous repeating dose
Study: NCT00570934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000IU Cholecalciferol P.O. Q.D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000IU Cholecalciferol P.O. Q.D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000IU Cholecalciferol P.O. Q.D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000IU Cholecalciferol P.O. Q.D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1 gm calcium as calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1 gm calcium as calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1 gm calcium as calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1 gm calcium as calcium carbonate
Study: NCT01141439

Intervention type: DRUG
Intervention: fluticasone propionate
Description: Initiation of FP (any dose) via MDI in steroid naive patient

Intervention type: DRUG
Intervention: Chlorofluorocarbon beclomethasone dipropionate
Description: Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
Study: NCT00570934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol
Description: 2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol
Description: 2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol
Description: 2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
Study: NCT04138329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein Technique
Description: In this group was used the Lichtenstein technique for inguinal repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Onstep Technique
Description: In this group was used the Onstep technique for inguinal repair
Study: NCT01525550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
Study: NCT04005612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 50,000 IU VD3 / week for 8 weeks
Study: NCT02625155

Intervention type: OTHER
Group type: OTHER
Intervention: Urine diagnostic testing as SOC, drug regimen changes per SOC

Intervention type: OTHER
Group type: OTHER
Intervention: Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
Study: NCT03480750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trientine dihydrochloride
Description: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
Study: NCT00570934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol
Description: 2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03480750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: pegylated liposomal doxorubicin 40mg/m2 IV D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 4 IV D1
Study: NCT00570934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01628861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyRestBreak 1.0
Description: Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education talk and leaflet
Description: A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education talk and leaflet
Description: A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
Study: NCT03854292

Intervention type: PROCEDURE
Intervention: Hysteroscopic tubal electrocoagulation
Description: Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.

Intervention type: PROCEDURE
Intervention: Hysteroscopic tubal electrocoagulation
Description: Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
Study: NCT02511600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progel Sealant
Description: After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Talcum Powder
Description: After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
Study: NCT03474120

Intervention type: PROCEDURE
Intervention: IVF treatment
Description: Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
Study: NCT02825927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral screen
Description: The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
Study: NCT00723892

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (PegIntron)
Description: Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
Study: NCT02511600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Questionnaire
Description: Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Questionnaire
Description: Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
Study: NCT06370234

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole body 18F-FDG Positron Emission Tomography
Description: The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
Study: NCT03209232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
Study: NCT00723892

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (PegIntron)
Description: Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week

Intervention type: DRUG
Intervention: Rebetol (Ribavirin)
Description: Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day

Intervention type: DRUG
Intervention: Rebetol (Ribavirin)
Description: Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day

Intervention type: BEHAVIORAL
Intervention: Psychotherapy support program
Description: Each site has implemented a psychotherapy support program.
Study: NCT04659889

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling (venesection)
Description: All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling (venesection)
Description: All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping.
Study: NCT00829543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guide-free sacroiliac corticosteroid injection
Description: guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
Study: NCT03209232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
Study: NCT01763424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus Nicotinamide
Description: Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Study: NCT04086290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RARP
Description: Radical prostatectomy + extended pelvic lymph node dissection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiotherapy to osseous lesions
Study: NCT02220660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL + BI 54903 XX FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03847272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone and ustekinumab treatment
Description: Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmologic examination
Description: Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: VFQ-25 and SF-36

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additional blood samples for immunomonitoring
Study: NCT03566849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KC group
Description: 1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT group
Description: 1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up
Study: NCT04029649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-1,3/1,6-D-Glucan
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 90 days
Study: NCT03678766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC)
Description: Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge.
Study: NCT04337879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folate
Description: Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folate
Description: Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.